This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Coronavirus Strain to Keep Telehealth Stocks in Demand
by Sapna Bagaria
Telemedicine is here to stay as the new coronavirus strain triggers a fear psychosis at large, thereby retaining solid demand for telehealth stocks.
QDEL vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
QDEL vs. RMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
5 Soaring MedTech Stocks to Buy for More Growth in 2021
by Urmimala Biswas
We have selected five MedTech growth stocks with further rooms for improvement in 2021.
5 Top Stocks With Attractive Sales Growth to Keep an Eye on
by Swayta Shah
A steady sales growth is key to survival for any company. Let's check Broadcom (AVGO), PennyMac Financial (PFSI), ResMed (RMD) Williams-Sonoma (WSM) & Parker-Hannifin (PH) as these are likely to witness solid sales growth.
Here's Why You Should Hold onto NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.
3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom
by Debanjana Dey
Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.
Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio
by Zacks Equity Research
Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Zacks.com featured highlights include: ResMed, The Toro Company, Masco Corp and Landstar System
by Zacks Equity Research
Zacks.com featured highlights include: ResMed, The Toro Company, Masco Corp and Landstar System
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
Medtronic (MDT) Releases Positive Study Results of RFA Therapy
by Zacks Equity Research
Medtronic's (MDT) OsteoCool RFA System is expected to provide better relief from debilitating pain for cancer patients.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Zimmer Biomet (ZBH) Shows Strong Recovery Amid COVID-19 Woes
by Zacks Equity Research
Owing to lack of clarity around the scope and duration of the coronavirus pandemic, Zimmer Biomet (ZBH) is unable to gauge the impact on its overall business in 2020.
Abbott (ABT) Gains CE Mark for Quantitative Serology Testing
by Zacks Equity Research
The test is set to be used on Abbott's (ABT) ARCHITECT and Alinity i platforms.
Abbott (ABT) Launches Immunity Boosting Hydration Solution
by Zacks Equity Research
Abbott's (ABT) latest hydration solution with specifically chosen nutrients along with optimal balance of electrolytes and glucose is expected to boost immunity.
NEOGEN (NEOG) Launches DNA Screening Tool for Canine Care
by Zacks Equity Research
NEOGEN's (NEOG) latest DNA screening tool is expected to aid veterinarians to provide healthy lifestyle recommendations for a longer and happier life for each pet and its family.
LabCorp's (LH) Pixel Kit Gets EUA for Over-the-Counter Use
by Zacks Equity Research
This approval is expected to increase access to LabCorp's (LH) COVID-19 testing, thereby broadening its customer base.
Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market
by Zacks Equity Research
Medtronic's (MDT) Carpediem CRRT system compares favorably with the traditional three times a week therapy session.
Bruker (BRKR) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker (BRKR) is optimistic about maintaining a robust product portfolio along with its continued COVID-19-led progress.
Illumina (ILMN)-Harvard Pilgrim Partner to Expand WGS Access
by Zacks Equity Research
Illumina (ILMN) signs agreement to expand the availability of WGS to enable faster and cost-effective diagnosis of genetic diseases in children.
QIAGEN (QGEN) Launches RUO Solution to Explore Immune Response
by Zacks Equity Research
QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.
LabCorp (LH) Covance Arms Shows Momentum Amid COVID-19 Woes
by Zacks Equity Research
In oncology too, LabCorp (LH) receives a significant award to be the partner of choice for late-stage oncology studies from a major pharmaceutical company.
NuVasive (NUVA) Focuses on Cervical Spine Portfolio Expansion
by Zacks Equity Research
The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.